BIO-TECH SYSTEMS, INC., founded in 1980, specializes in market research and strategic planning, where technological and scientific insight is important. This focuses on emerging technologies where it is necessary to make accurate forecasts of future market demand and communicate effectively with many levels of management and end-users. One objective is to assess technological risk and target new products and services effectively in order to generate the best market response.
Bio-Tech focuses in five product areas with comprehensive reports that analyze market opportunities in each segment. The product areas include Diagnostic and Therapeutic Radiopharmaceuticals, PET radiopharmaceuticals and PET imaging, Medical Imaging Contrast Media, Radiotherapy and Immunotherapy products, and Brachytherapy products.
The methodology utilized has been developed over 20 years in this field focusing on both researchers and clinicians in these fields as well as knowledgeable industry sources. This provides insight with respect to market trends as well as new technology entering the pipeline. Bio Tech also benefits from its large internal database that is regularly updated. As a result, the company’s forecasts are both conservative and realistic and can be used with confidence in market planning and evaluation of new business opportunities.
The company's founder, Marvin Burns, has been active in the medical industry and hospital community for over 20 years and has prepared numerous market research reports that have been widely distributed. The reports have served as a platform for assessing new ventures and business opportunities across a broad spectrum of products. Burns has also served as a consultant to many of the major pharmaceutical and medical imaging companies and venture groups in evaluating new product and market opportunities.
BIO-TECH SYSTEMS has recently released the following market research reports. Click the links below to jump down and learn more.
Report #300: THE MARKET FOR PET RADIOPHARMACEUTICALS & PET IMAGING analyzes the dynamic market for PET procedures and its effect as a driving force in molecular imaging. This has resulted in a rapid increase in the worldwide market for PET radiopharmaceuticals and demand for high performance PET scanners. International market growth has been vigorous as the technology becomes more widely available and the distribution of FDG improves, adding overall momentum. Although reimbursement in the U.S. has been reduced recently, the number of approved indications has increased and it is likely that Medicare will eventually move toward open coverage for PET, similar to CT and MR. New PET tracers are also in late stage development for diagnosing Alzheimer's disease and assessing myocardial perfusion in cardiology. In addition, new oncology agents will help in treatment monitoring and therapy planning for most common cancers, increasing the utilization of PET worldwide.
Report #290: THE U.S. MARKET FOR BRACHYTHERAPY PRODUCTS provides a comprehensive analysis of the markets for brachytherapy products. The report discuss the prospects for prostate seed implants and the effect of competing modalities, the rapidly growing market for partial breast irradiation devices and gynecological brachytherapy, new markets for electronic brachytherapy using miniaturized x-ray technology, sales growth for irradiated microspheres for liver cancer and the large emerging brachytherapy market for treating macular degeneration. The report also examines the continuing prospects for endovascular brachytherapy, the market for brain cancer brachytherapy and other post-surgical applications amenable to brachytherapy. The report considers the trade-offs between LDR (low dose rate) and HDR (high dose rate) brachytherapy, the integration of brachytherapy with other treatment modalities and the increasing number of options available to both clinicians and patients as new technology enters the mainstream. Many new brachytherapy products have been introduced recently with rapid growth in procedure volume. There are also new products on the threshold, with introduction scheduled in the near future. This will stimulate further growth and encourage wider acceptance of brachytherapy with improved outcomes for many patients.
Report #270: THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS provides a comprehensive analysis of the markets for diagnostic radiopharmaceuticals. This considers the expiring patent for Cardiolite and the introduction of generic sestamibi. It also covers all aspects of nuclear cardiology, functional nuclear medicine, targeted oncology and PET imaging. This includes emerging applications in imaging myocardial infarction, congestive heart failure, in vivo infection imaging and new molecular imaging products for oncology. It also considers diagnostic applications in endocrine cancer, prostate cancer, breast cancer and multiple solid tumors. New molecular imaging and therapeutic modalities are being developed based on apoptosis, angiogenesis and PLE (Phospho-Lipid Ether) tumor targeting that will employ both SPECT and PET imaging. This will include new oncology products for diagnosing and monitoring cellular response to therapy. These molecular imaging platforms will also have therapeutic applications, increasing their versatility and usefulness Therapeutic radiopharmaceuticals will also employ molecular imaging to assess biodistribution and aid in developing patient specific dosimetry necessary for optimizing dosage and evaluating patient response to therapy. This stimulus to nuclear medicine will encourage more investment from biopharmaceutical companies and venture groups that will ultimately promote future market growth.
Report #260: THE U.S. MARKET FOR MEDICAL IMAGING CONTRAST MEDIA provides a comprehensive analysis of the markets for medical imaging contrast media in all modalities including X-ray, CT, MRI and ultrasound. Noninvasive vascular imaging will increase dramatically, replacing traditional angiography in many cases. New molecular imaging and therapeutic modalities are also being developed based on apoptosis, angiogenesis and imaging of growth receptors that are expressed in a large number of cancers. This will bring imaging modalities such as MRI, CT, PET and ultrasound closer together, increasing the sensitivity and specificity of diagnoses. Ultrasound contrast procedures will also become more productive, since clinicians and sonographers have implemented protocols that are simpler and more effective to use. There is also excellent likelihood that the approved indications for ultrasound contrast agents will be extended to perfusion imaging in the future. This technical influx will help all segments of the contrast media field and will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field.
Report #230: THE WORLD MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS analyzes the markets for therapeutic radiopharmaceuticals including current and emerging applications for lymphoma, colon cancer, lung cancer, prostate cancer, breast cancer, endocrine cancer and other cancers resistant to traditional therapies. There has been a surge in research activity to expand applications for therapeutic radiopharmaceuticals employing more sophisticated targeting methodologies and more appropriate therapeutic isotopes for the tumors being treated. This has prompted increased interest in alpha emitters, where the shorter particle range and high-energy deposition can be used to advantage to destroy DNA directly, minimizing toxicity and protecting neighboring healthy cells. The growing use of molecular imaging is also helping to control and monitor dosage for increased safety and effectiveness. As these products enter the mainstream, there will be others in the pipeline for treating a variety of cancers. This will stimulate investment with greater support from large pharmaceutical companies. One motivator is the potential return on investment and the high price of these products, which is justified by their unique capabilities.
Marvin Burns is president of BIO-TECH SYSTEMS, Inc., founded in 1980 to perform market research for companies in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, radiotherapy and immunotherapy products, brachytherapy, PET imaging, contrast agents, and interventional cardiology, which have been widely distributed. Burns has served as a consultant to many international firms and venture groups in strategic planning and development of new business opportunities. He has also been Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry, reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School’s advanced management program. He has over 100 publications and 15 patents and invention disclosures. Prior to forming BIO-TECH SYSTEMS, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management.
mburns_cv.doc
-OR-
mburns_cv.pdf
Back to Top
Send
this page to a friend